An interventional study of back sleep positioning and side sleep positioning in Obstructive Sleep Apnea and Cleft Palate, sponsored by Manchester University NHS Foundation Trust. Recruiting at 11 sites in United Kingdom. Open to participants aged 21 Days to 35 Days. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Manchester University NHS Foundation Trust · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one is the 4th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2022, is one of 21 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 36th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:
Virginia Hawkins · Sites in United Kingdom
Ages 18+
Inspire Medical Systems, Inc. · Sites in United Kingdom, Austria, Belgium and 4 more countries
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Children's Health Ireland · Sites in United Kingdom, Ireland
Ages 6 mo–16 yrs
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 21 Days to 35 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 244 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 58 across the 26 interventional studies, 102 across the 28 observational. Of the 36 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Manchester University NHS Foundation Trust is the lead sponsor of 140 studies on the registry; 27 are open to participants now.
Manchester University NHS Foundation Trust has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
2 of the studies in Sleep Apnea, Obstructive with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07497412King's College LondonThe Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea | 2026-11 |
| NCT06030349Children's Health IrelandClinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down Syndrome | 2027-11-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The craniofacial abnormalities found in infants and children with cleft palate (CP) lead to increased risk of obstructive sleep apnoea (OSA). In children and adults sleep position is known to influence the patency of the airway during sleep. Altering sleep position in infants with CP may offer a 'low-cost, high impact' intervention to limit the negative impacts of OSA on child development.
Children with CP are at increased risk of impairment in learning, memory and cognition, with OSA representing an additional risk to cognitive development. Infants with CP are at risk of poor weight gain and 'failure to thrive', which can be further exacerbated by co-existing OSA.
The design and conduct of the proposed randomised controlled trial will benefit from lessons learned from both the feasibility and other previous studies. Investigators demonstrated that existing advice given about sleep position varied significantly with some centres recommending back-lying and others side-lying. Sample size calculations were based on this multi-source data. Parents in the feasibility study knew that sleep position advice for infants with CP changes regularly. They understood why not adhering to 'national guidance' (DoH 2009, Back to Sleep) could be necessary as their infants are "different to normal infants".
How will this study benefit infants with cleft palate and their parents? The proposed study will eliminate the current uncertainty and variability in advice provided to parents of infants with CP, whilst potentially limiting the negative impact of OSA on development. This work has been prioritised and received unanimous support from Cleft Lip and Palate Association (CLAPA), Craniofacial Society Great Britain and Ireland (CFSGBI) and Clinical Nurse Specialists. Aim.To determine the clinical effectiveness in infants with CP of side-lying as compared to back-lying sleep positioning in reducing oxygen desaturation resulting from OSA.
The primary aim of this project is to determine the clinical effectiveness in infants with cleft palate (CP) of side-lying as compared to back-lying sleep positioning in reducing oxygen desaturation resulting from obstructive sleep apnoea (OSA). This will be achieved:
A randomised controlled trial (RCT) of side-lying compared with back-lying sleep positioning in reducing oxygen desaturation resulting from OSA in infants with CP. The design and conduct of the study will benefit from lessons learned from the feasibility and other previous studies. All parents in the feasibility study indicated strong interest to participate in further studies evaluating the effects of sleep position. Infants meeting the eligibility criteria will be randomised to side-lying or back-lying in a ratio 1:1 using a minimisation routine incorporating a random element to reduce predictability. Minimisation factors will be clinical site and syndrome suspected or indicated (yes / no). Allocations will be delivered via a password-protected web-based system. The allocated position will only be used on the day(s) when the infant is monitored for the study purposes. Thereafter, parents will be free to revert back to the standard sleep position as advised by their cleft centre, should it be different than that used for the monitoring period. All centres represented at the preparatory meeting with the United Kingdom (UK) Lead Clinical Nurse Specialist group, confirmed that the side-lying position was recommended in some infants at their centre, irrespective of whether it was the standard advice used. As such, all centres had experience of the side-lying position. It was decided not to change the specific advice that centres give to parents regarding how to position the infant in a side-lying position, but any standard written or verbal information would be collected by the study documents.
An internal pilot will investigate participants' opinions about their participation in the study. Using bespoke questionnaires participants' experience will be assessed and it will be decided how it could be improved. After 6 months questionnaire results will be analysed and if necessary study amendments will be put in place to reflect participants' opinions.
Data from the feasibility study and published studies have reported estimates of the standard deviation (SD) of the primary outcome ODI-4 in the side-lying infants at four weeks to range from 8 to 11 units, with a higher SD observed in the back-lying group. The observed difference in mean ODI-4 between the side-lying and back-lying infant cohorts was 15 units (a standardised effect size of 0.91). Investigators considered a smaller but more realistic difference in means of five units to be a clinically important difference (SD 10), a standardised effect size of 0.5. The sample size calculation comparing two means with unequal variances for the primary outcome was, therefore, based on a standardised effect size of 0.5. To account for potential unequal variances in each group a variance ratio of 2 was used in the calculations. To detect a difference of 0.5 standard deviation score (SDS) with 80% power and alpha equal to 0.05 would require 96 infants to be monitored in each arm of the trial (a total of 192 participants). Informed by the multicentre feasibility and oximetry studies the sample size will be inflated to 244 participants in the RCT, to allow for potential attrition of 21%.
This will follow a pre-specified and approved statistical analysis plan. The primary analysis of the RCT data will use intention-to-treat. Baseline data will be analysed to assess the comparability of the demographic and clinical characteristics of the participants. Data from the trial arms will be compared using generalised linear models and adjusted for minimisation covariates where appropriate. Estimates of treatment effect size will be reported as differences in means for continuous outcomes, and risk ratios for dichotomous outcomes and reported along with 95% confidence intervals. Subgroup analyses will explore the effects of sleep position on infants with and without suspected associated syndromes through subgroup treatment interactions, at a stricter alpha level 0.01.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
sleep on the back
Other: back sleep positioning
sleep on the side
Other: side sleep positioning
sleeping on the back.
sleeping on the side
Oxygen saturation during sleep at 1 month of age
Oxygen saturation during sleep at 1 month of age (expressed as 4% oxygen desaturation index, ODI-4). Oximetry is considered the mainstay of assessment of oxygenation in infants and will be the primary outcome measurement instrument. The ODI-4 represents the average number of times that oxygen saturation falls by at least 4% from baseline every hour.
Time frame: 1 month of age
SPO2 mean
mean oxygen saturation
Time frame: completed at 1 month
SPO2 nadir
nadir oxygen saturation
Time frame: completed at 1 month
Total sleep time
the proportion of total sleep time (TST) with oxygen saturation below: 97%, 95%, 90% and 80%
Time frame: completed at 1 month.
Oxygen saturation during sleep at 1 month of age
Oxygen saturation during sleep at 1 month of age (expressed as 3% oxygen desaturation index, ODI-3). Oximetry is considered the mainstay of assessment of oxygenation in infants and will be the primary outcome measurement instrument. The ODI-3 represents the average number of times that oxygen saturation falls by at least 3% from baseline every hour.
Time frame: 1 month of age
Weight
child's weight
Time frame: completed at 1 month.
Length
participant's length
Time frame: 1 month of age
Head circumference
participant's head circumference
Time frame: 1 month of age
Number of participants with Adverse events.
Number of participants experiencing Adverse events during the trial
Time frame: From consent for up to 2 weeks
Plan to share: No
Started Jan 2022 (actual). Primary completion is estimated for Sep 2024, 32 months after the start.
Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 32 months is close to that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Manchester University NHS Foundation Trust →